Search results for "Apolipoprotein B"

showing 10 items of 170 documents

Resistance Training Induces Antiatherogenic Effects on Metabolomic Pathways

2019

INTRODUCTION Arising evidence suggests that resistance training has the potential to induce beneficial modulation of biomarker profile. To date, however, only immediate responses to resistance training have been investigated using high-throughput metabolomics whereas the effects of chronic resistance training on biomarker profile have not been studied in detail. METHODS A total of 86 recreationally active healthy men without previous systematic resistance training background were allocated into (i) a resistance training (RT) group (n = 68; age, 33 ± 7 yr; body mass index, 28 ± 3 kg·m) and (ii) a non-RT group (n = 18; age, 31 ± 4 yr; body mass index, 27 ± 3 kg·m). Blood samples were collecte…

AdultMalemedicine.medical_specialtyMagnetic Resonance SpectroscopyWeight LiftingApolipoprotein BLipoproteinsPhysical Therapy Sports Therapy and Rehabilitation030204 cardiovascular system & hematologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsInternal medicinemedicineMetabolomeHumansMetabolomicsOrthopedics and Sports MedicineLongitudinal StudiesMuscle StrengthAmino Acids2. Zero hungerbiologymedicine.diagnostic_testCholesterolbusiness.industryFatty AcidsResistance TrainingCholesterol LDL030229 sport sciencesAtherosclerosisLipidsDiet3. Good healthCholesterolEndocrinologychemistryBody CompositionLean body massbiology.proteinBiomarker (medicine)businessLipid profileBody mass indexBiomarkersLipoproteinMedicine & Science in Sports & Exercise
researchProduct

A Novel APOB Mutation Identified by Exome Sequencing Cosegregates With Steatosis, Liver Cancer, and Hypocholesterolemia

2013

Objective— In familial hypobetalipoproteinemia, fatty liver is a characteristic feature, and there are several reports of associated cirrhosis and hepatocarcinoma. We investigated a large kindred in which low-density lipoprotein cholesterol, fatty liver, and hepatocarcinoma displayed an autosomal dominant pattern of inheritance. Approach and Results— The proband was a 25-year-old female with low plasma cholesterol and hepatic steatosis. Low plasma levels of total cholesterol and fatty liver were observed in 10 more family members; 1 member was affected by liver cirrhosis, and 4 more subjects died of either hepatocarcinoma or carcinoma on cirrhosis. To identify the causal mutation in this f…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BNonsense mutationBiologyArticlehypobetaliproteinemia type 1Hypobetalipoproteinemiasexome fatty liver hypobetalipoproteinemia familial 2Young Adultsymbols.namesakeInternal medicinemedicineHumansExomeHEPATOCELLULAR CARCINOMAExomeExome sequencingApolipoproteins Bfatty liverFamily HealthGeneticsSanger sequencingLiver NeoplasmsFatty liverMiddle AgedHEPATOCELLULAR CARCINOMA; exome; fatty liver; hypobetaliproteinemia type 1medicine.diseasePedigreeFatty LiverHypocholesterolemiaCholesterolEndocrinologyCodon Nonsensebiology.proteinsymbolsFemaleCardiology and Cardiovascular MedicineLiver cancerexomeArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholeste…

2017

Homozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis. Patients are often poorly responsive to conventional lipid-lowering therapies that upregulate LDL-receptor expression.1 Lomitapide inhibits microsomal triglyceride transfer protein, which lipidates nascent apolipoprotein (apo)B-containing lipoproteins. In a pivotal 78-week open-label trial, lomitapide, titrated to the maximal tolerable dose, decreased LDL-C by 50% at the end of the efficacy phase (week 26) in patients with homozygous familial hypercholesterolemia.2 The principal …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BSocio-culturaleFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologyMicrosomal triglyceride transfer proteinLDLTimeSudden cardiac deathHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumans030212 general & internal medicineAdverse effectlomitapidebiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLlomitapide; Adult; Anticholesteremic Agents; Benzimidazoles; Carrier Proteins; Cholesterol LDL; Female; Humans; Hyperlipoproteinemia Type II; Male; Timemedicine.diseaseLomitapideCholesterolEndocrinologychemistrybiology.proteinBenzimidazolesFemalelipids (amino acids peptides and proteins)lomitapide; Cardiology and Cardiovascular Medicine; Physiology (medical)Carrier ProteinsCardiology and Cardiovascular MedicinebusinessLipoproteinCirculation
researchProduct

Evaluation of cardiovascular risk and oxidative stress parameters in hypercholesterolemic subjects on a standard healthy diet including low-fat milk …

2010

A healthy diet and plant sterols (PS) are recommended for reducing low-density lipoprotein (LDL) cholesterol and, subsequently, the risk of premature cardiovascular disease PS mediate a decrease in fat-soluble vitamin concentration, which can lead to a general impairment of antioxidative defenses and an increase in oxidative stress. Thus, we evaluated the effects of a healthy diet, including PS-enriched low-fat milk, on cardiovascular risk and oxidative stress parameters in hypercholesterolemic subjects. This was a randomized parallel trial employing 40 subjects and consisting of two 3-month intervention phases. After 3 months on a standard healthy diet, subjects were divided into two inter…

AdultVitaminmedicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and MetabolismHypercholesterolemiaClinical Biochemistrymedicine.disease_causeBiochemistrychemistry.chemical_compoundInternal medicinemedicineAnimalsHumansMolecular BiologyAgedNutrition and Dieteticsbiologymedicine.diagnostic_testCholesterolPhytosterolsMiddle AgedOxidative StressMilkEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Apolipoprotein A1CryptoxanthinLipid profileOxidative stressLipoproteinThe Journal of Nutritional Biochemistry
researchProduct

A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia.

2008

Autosomal dominant hypercholesterolemia (ADH) is a genetic disorder characterized by increased low-density lipoprotein (LDL)-cholesterol levels, leading to high risk of premature cardiovascular disease. More than 900 mutations in LDL receptor, six in APOB and 10 in PCSK9 have been identified as a cause of the disease in different populations. All known mutations in PCSK9 causing hypercholesterolemia produce an increase in the enzymatic activity of this protease. Up to now, there are data about the implication of PCSK9 in ADH in a low number of populations, not including a Spanish population.The objective of the study was to study the prevalence of PCSK9 mutations in ADH Spanish population.W…

Adultmedicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and MetabolismClinical BiochemistryGene ExpressionTransfectionBiochemistryPolymorphism Single NucleotideHyperlipoproteinemia Type IIPCSK9 GeneMiceEndocrinologyGene FrequencyInternal medicinemedicineAnimalsHumansPromoter Regions GeneticAllele frequencyGeneCells CulturedGeneticsbiologyBase SequencePCSK9Biochemistry (medical)Serine EndopeptidasesGenetic disorderHyperlipoproteinemia Type IIaMiddle Agedmedicine.diseaseEndocrinologySpainCase-Control StudiesLDL receptorbiology.proteinNIH 3T3 Cellslipids (amino acids peptides and proteins)Mutant ProteinsProprotein ConvertasesProprotein Convertase 9The Journal of clinical endocrinology and metabolism
researchProduct

Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.

2013

Abstract Objective To determine the spectrum of gene mutations and the genotype–phenotype correlations in patients with Autosomal Dominant Hypercholesterolemia (ADH) identified in Italy. Methods The resequencing of LDLR , PCSK9 genes and a selected region of APOB gene were conducted in 1018 index subjects clinically heterozygous ADH and in 52 patients clinically homozygous ADH. The analysis was also extended to 1008 family members of mutation positive subjects. Results Mutations were detected in 832 individuals: 97.4% with LDLR mutations, 2.2% with APOB mutations and 0.36% with PCSK9 mutations. Among the patients with homozygous ADH, 51 were carriers of LDLR mutations and one was an LDLR / …

Adultmedicine.medical_specialtyHeterozygoteSettore MED/09 - Medicina InternaApolipoprotein BCoronary DiseaseBiologyGene mutationmedicine.disease_causeHyperlipoproteinemia Type IITendonschemistry.chemical_compoundReference ValuesInternal medicinemedicineXanthomatosisHumansGeneAllelesGenetic Association StudiesAgedGeneticsMutationCholesterolPCSK9Cholesterol HDLSerine EndopeptidasesSmokingAlcohol Dehydrogenasenutritional and metabolic diseasesCholesterol LDLMiddle AgedEndocrinologyPhenotypechemistryItalyLDL receptorMutationbiology.proteinAutosomal dominanthypercholesterolemia LDL receptor Apolipoprotein B PCSK9 Mutationslipids (amino acids peptides and proteins)Allelic heterogeneityFemaleProprotein ConvertasesProprotein Convertase 9Cardiology and Cardiovascular MedicineAtherosclerosis
researchProduct

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.

2009

OBJECTIVE: Dyslipidaemia is very common in patients with polycystic ovary syndrome (PCOS) but, beyond plasma lipids, atherogenic lipoprotein (Lp) and apolipoprotein (apo) alterations are still ill defined. DESIGN: We measured concentrations of apoB, Lp(a) and small, dense low-density lipoprotein (LDL) in 42 patients with PCOS [age: 28 +/- 7 years, body mass index (BMI): 27 +/- 5 kg/m(2)] vs. 37 age- and BMI-matched healthy controls. METHODS: Elevated Lp(a) levels considered were those > 30 mg/dl while elevated apoB concentrations were those > 100 g/l. RESULTS: Polycystic ovary syndrome showed increased triglycerides levels (p = 0.0011) and lower high-density lipoprotein (HDL)-cholesterol co…

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein B10265 Clinic for Endocrinology and Diabetology610 Medicine & health2700 General MedicineSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundYoung AdultRisk FactorsInternal medicinemedicinedyslipidemia lipoproteins polycystic ovary syndromeHumansProspective cohort studyApolipoproteins BDyslipidemiasbiologyCholesterolbusiness.industryVascular diseaseCase-control studynutritional and metabolic diseasesGeneral MedicineCholesterol LDLmedicine.diseasePolycystic ovaryEndocrinologychemistry10036 Medical ClinicCardiovascular DiseasesCase-Control Studiesbiology.proteinlipids (amino acids peptides and proteins)FemalebusinessBody mass indexLipoproteinLipoprotein(a)Polycystic Ovary SyndromeInternational journal of clinical practice
researchProduct

Plasma lipid, apolipoprotein and Lp(a) levels in elderly normolipidemic women: Relationships with coronary heart disease and longevity

1995

The relation between plasma lipids and coronary heart disease (CHD) in the elderly is still debated, as well as the proposed role of lipoproteins as markers of longevity. In this study both normolipidemic elderly and middle-aged women with CHD showed higher triglycerides and apolipoprotein B levels and lower high-density lipoprotein (HDL)-cholesterol and apolipoprotein A-I levels in comparison with age-matched subjects without CHD. In the middle-aged group, hypertension and HDL-cholesterol levels and, in the elderly group, only HDL-cholesterol levels were independently associated with CHD. No significant difference was found between a group of healthy centenarians and elderly and middle-age…

Agingmedicine.medical_specialtyApolipoprotein Bmedia_common.quotation_subjectLipoproteinsLongevityPhysiologyCoronary DiseaseAge DistributionReference ValuesRisk FactorsInternal medicinePlasma lipidsmedicineHumansmedia_commonAgedAged 80 and overAnalysis of Variancebiologybusiness.industrySignificant differenceLongevityMiddle AgedhumanitiesMiddle ageCoronary heart diseasePostmenopauseEndocrinologyApolipoproteinsLogistic ModelsCorrelation analysisbiology.proteinlipids (amino acids peptides and proteins)FemaleGeriatrics and GerontologybusinessLipoproteins HDLLipoproteinLipoprotein(a)
researchProduct

Associations Between Lipoprotein Subfractions and Area and Density of Abdominal Muscle and Intermuscular Adipose Tissue: The Multi-Ethnic Study of At…

2021

Skeletal muscle quantity and quality decrease with older age, which is partly attributed to ectopic fat infiltration and has negative metabolic consequences. To inform efforts to preserve skeletal muscle with aging, a better understanding of biologic correlates of quantity and quality of muscle and intermuscular adipose tissue (IMAT) is needed. We used targeted lipidomics of lipoprotein subfractions among 947 Multi-Ethnic Study of Atherosclerosis participants to provide a detailed metabolic characterization of area and density of abdominal muscle and IMAT. Serum lipoprotein subfractions were measured at the first visit using 1H-Nuclear Magnetic Resonance spectroscopy. Muscle and IMAT area (…

Agingmedicine.medical_specialtyVery low-density lipoproteinApolipoprotein BPhysiologyMedical PhysiologyAdipose tissueCardiovascularlipidschemistry.chemical_compoundAbdominal musclesmyosteatosisPhysiology (medical)Internal medicineLipidomicsmedicineQP1-981Psychologyskeletal muscleOriginal Researchbiologybusiness.industryCholesterolSkeletal muscleAtherosclerosislipoproteinsmedicine.anatomical_structureEndocrinologychemistrybiology.proteinlipidomicsbusinessmetabolismLipoproteinFrontiers in Physiology
researchProduct

Familial Amyloid Polyneuropathy

2013

Familial amyloid polyneuropathy (FAP; also known as familiar amyloidosis and hereditary amyloidosis) is an autosomal dominant inherited disease due to mutations of the transthyretin (TTR) gene coding for the corresponding protein, consisting of 127 amino acids. The gene is located on chromosome 18q. More than 100 different mutations are known. Other mutant precursor proteins produced in the liver, such as apolipoprotein I and II, lysozyme and fibrinogen Aα, may be of etiological importance as well. Amyloidogenic mutations of the TTR gene lead to decreased stability of the corresponding protein and subsequently to extracellular deposition of amyloid in several tissues (peripheral and autonom…

Amyloid Neuropathies Familialmedicine.medical_specialtyAmyloidbiologyApolipoprotein Bbusiness.industrymedicine.medical_treatmentAmyloidosisGastroenterologyGeneral MedicineDiseaseLiver transplantationmedicine.diseaseGastroenterologyLiver TransplantationTransthyretinAmyloid NeuropathyInternal medicinePrevalencebiology.proteinmedicineHumansPrealbuminbusinessPolyneuropathyDigestive Diseases
researchProduct